Salix Pharmaceuticals, Ltd. announced the successful outcome of TARGET 3 � a Phase III randomized, double-blind, placebo-controlled study to evaluate...
Norgine B.V. has presented new analyses demonstrating the cost effectiveness of Xifaxan/Targaxan (rifaximin-alfa 550mg) treatment in Belgian and Dutch cirrhotic...
Bausch Health Companies Inc. and its gastroenterology business Salix Pharmaceuticals, announced the U.S. District Court of Delaware issued an Oral Order in the matter of Salix Pharmaceuticals, Ltd. et al v.
Norgine has highlighted results of a real world study showing significant reductions in the number and length of hospitalisations when...
Actavis plc announced that Viberzi (eluxadoline) was approved by the FDA as a twice-daily, oral treatment for adults suffering from...
Norgine B.V. highlighted new data from a UK retrospective study showing that rifaximin-a prescribed for the recurrence of overt hepatic...